Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2023-04-26 Regulatory Filings
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023
Regulatory Filings Classification · 90% confidence The document is explicitly titled "Press Release" and announces that new data on two company assets (NCX 470 and NCX 1728) were presented at the ARVO 2023 Annual Meeting. It details the findings from posters and presentations, discusses ongoing clinical trials (Mont Blanc, Denali), and provides company background. This format—a formal announcement of recent scientific/clinical updates intended for the public and investors—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it focuses on scientific/pipeline updates rather than just financial results highlights, it fits best as a general announcement. Given the context of presenting scientific data, it is a specific type of corporate communication. However, among the provided codes, 'ER' (Earnings Release) often encompasses major operational/pipeline updates released concurrently with or near financial reporting periods, or 'RNS' (Regulatory Filings) as a general announcement. Since this is a scientific data presentation announcement, and not a formal financial results summary (ER), 'RNS' is the most appropriate fallback for a non-standard, material corporate announcement that doesn't fit other specific categories like M&A or Capital Change. The length (6816 chars) is substantial, suggesting it is the primary content, not just a brief notification (RPA).
2023-04-26 English
Number of voting rigts as of April 24, 2023
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it is a 'MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS' as of a specific date (April 24, 2023), referencing French commercial code and AMF regulations. This content details the total share count and voting rights, which is a specific regulatory disclosure related to capital structure and ownership transparency. This aligns best with the 'Share Issue/Capital Change' (SHA) category, as it reports the current state of the share capital, or potentially 'Regulatory Filings' (RNS) if a more specific category isn't available. Given the focus on the total number of shares and voting rights, SHA is the most precise fit among the provided options, as it directly relates to the capital structure reporting.
2023-04-24 English
Nombre de droits de vote au 24 avril 2023
Share Issue/Capital Change Classification · 95% confidence The document is titled "PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE" (Monthly publication of the number of shares comprising the capital and the total number of voting rights). It explicitly references French regulatory articles (Code de Commerce and AMF General Regulation) and provides a snapshot of the total shares and voting rights as of April 24, 2023. This type of regular disclosure regarding share capital and voting rights, especially when published monthly, is a specific regulatory filing requirement. It does not fit the definitions for Annual Report (10-K), Earnings Release (ER), or a general announcement of a report (RPA). Since it is a specific, recurring regulatory disclosure that doesn't fit the other specialized codes (like DIRS, DIV, or CAP), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous, mandatory disclosure, or potentially under 'Share Issue/Capital Change' (SHA) if the focus was on a change, but here it is a routine monthly update on the existing structure. Given the options, RNS is the most appropriate fallback for a routine, non-standardized regulatory disclosure not covered elsewhere. However, since it is specifically about the capital structure and voting rights, SHA might be considered, but SHA usually implies a *change*. Since this is a routine monthly report on the *current* state, RNS is safer as a general regulatory filing.
2023-04-24 French
Nicox : Assemblée Générale Ordinaire 2023 le 1er juin 2023
AGM Information Classification · 98% confidence The document is titled "Communiqué de presse" (Press Release) and explicitly announces the date and details for the "Assemblée Générale Ordinaire 2023" (Ordinary General Meeting 2023) scheduled for June 1, 2023. This content directly relates to the meeting of shareholders and the materials associated with it. The definition for AGM Information (AGM-R) covers "Presentations and materials shared during the Annual General Meeting (AGM)". Although this is a press release *announcing* the AGM, the core subject matter is the AGM itself, making AGM-R the most specific fit over a general RPA or RNS, as it pertains to the formal shareholder meeting structure and logistics.
2023-04-24 French
Nicox: 2023 Ordinary Shareholder Meeting to be held on June 1st, 2023
AGM Information Classification · 98% confidence The document is explicitly titled "Press Release" and announces the date and details for the "2023 Ordinary Shareholder Meeting" (AGM). It discusses documents being made available to shareholders, voting procedures, and a potential second call date. This content directly relates to the preparation and scheduling of the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R). Although it is a press release, its core subject matter is the AGM itself, making AGM-R more specific than the general Regulatory Filings (RNS). The document length (5149 chars) is substantial enough that it is not merely a placeholder announcement (RPA).
2023-04-24 English
Nicox Provides First Quarter 2023 Financial and Business Highlights
Earnings Release Classification · 100% confidence The document is explicitly titled "Press Release" and provides "First Quarter 2023 Financial and Business Highlights." It details key financial metrics (Net revenue, cash position) for the first quarter (Q1 2023) and discusses corporate updates and future milestones. This structure—a brief announcement summarizing key financial results for a specific interim period (quarterly)—aligns perfectly with the definition of an Earnings Release (ER). Although it contains some financial data, it is a summary press release, not the comprehensive Interim/Quarterly Report (IR) or the full Annual Report (10-K). The document also mentions that the audit procedures for the year-end 2022 accounts are ongoing and the certification report will follow the annual report publication, confirming this is not the full audited report. Q1 2023
2023-04-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.